Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1981 Aug;40(4):350–354. doi: 10.1136/ard.40.4.350

Prostaglandin E1 infusions for vascular insufficiency in progressive systemic sclerosis.

M F Martin, P M Dowd, E F Ring, E D Cooke, P A Dieppe, J D Kirby
PMCID: PMC1000727  PMID: 7259326

Abstract

Twelve patients with systemic sclerosis (SS) and severe Raynaud's phenomenon received infusions of prostaglandin E1 (PGE1) at a dose of 6-10 ng/kg/min, with either saline or 5% dextrose, for 72 hours in a single-blind cross-over study. The infusions were administered intravenously by centrally positioned catheters. Infusions were well tolerated with only mild side effects. Following the PGE1 infusion cold tolerance improved and attacks of Raynaud's phenomenon were less frequent, less severe, and shorter in duration. This subjective improvement was maintained for several weeks in most patients, and 2 noted healing of ischaemic ulcers. There was no significant change in objective measurements of hand function after either infusion. However, pain measured on a 10 cm visual analogue scale improved 2.19 cm with PGE1 and only 0.91 cm with normal saline (P less than 0.05). Temperature of the fingers and hands recorded by thermography did not change significantly with saline infusions, but did rise during PGE1 infusions (mean rise 2.0 degrees C at 48 hours, p less than 0.001), and was maintained when measured again 2 weeks later (mean rise 1.56 degrees C, p less 0.001). PGE1 may therefore be suitable treatment for Raynaud's phenomenon and the vascular insufficiency of systemic sclerosis and other connective tissue diseases.

Full text

PDF
354

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bach M. A. Differences in Cyclic AMP Changes after Stimulation by Prostaglandins and Isoproterenol in Lymphocyte Subpopulations. J Clin Invest. 1975 May;55(5):1074–1081. doi: 10.1172/JCI108008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Campbell P. M., LeRoy E. C. Pathogenesis of systemic sclerosis: a vascular hypothesis. Semin Arthritis Rheum. 1975 May;4(4):351–368. doi: 10.1016/0049-0172(75)90017-7. [DOI] [PubMed] [Google Scholar]
  3. Carlson L. A., Eriksson I. Femoral-artery infusion of prostaglandin E 1 in severe peripheral vascular disease. Lancet. 1973 Jan 20;1(7795):155–156. doi: 10.1016/s0140-6736(73)90233-x. [DOI] [PubMed] [Google Scholar]
  4. Carlson L. A., Olsson A. G. Intravenous prostaglandin E1 in severe peripheral vascular disease. Lancet. 1976 Oct 9;2(7989):810–810. doi: 10.1016/s0140-6736(76)90653-x. [DOI] [PubMed] [Google Scholar]
  5. Coffman J. D. Drug therapy: vasodilator drugs in peripheral vascular disease. N Engl J Med. 1979 Mar 29;300(13):713–717. doi: 10.1056/NEJM197903293001305. [DOI] [PubMed] [Google Scholar]
  6. Collins A. J., Ring E. F., Cosh J. A., Bacon P. A. Quantitation of thermography in arthritis using multi-isothermal analysis. I. The thermographic index. Ann Rheum Dis. 1974 Mar;33(2):113–115. doi: 10.1136/ard.33.2.113. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Cormane R. H., Hamerlinck F., Nunzi E. Antibodies eluted from lymphoid cell membrane. Occurrence in certain varieties of scleroderma. Arch Dermatol. 1979 Jun;115(6):709–712. [PubMed] [Google Scholar]
  8. DE TAKATS G., FOWLER E. F. Raynaud's phenomenon. JAMA. 1962 Jan 6;179:1–8. doi: 10.1001/jama.1962.03050010003001. [DOI] [PubMed] [Google Scholar]
  9. Dunn C. J., Willoughby D. A., Giroud J. P., Yamamoto S. An appraisal of the interrelationships between prostaglandins and cyclic nucleotides in inflammation. Biomedicine. 1976;24(4):214–220. [PubMed] [Google Scholar]
  10. Fauci A. S., Haynes B., Katz P. The spectrum of vasculitis: clinical, pathologic, immunologic and therapeutic considerations. Ann Intern Med. 1978 Nov;89(5 Pt 1):660–676. doi: 10.7326/0003-4819-89-5-660. [DOI] [PubMed] [Google Scholar]
  11. Fleischmajer R., Damiano V., Nedwich A. Alteration of subcutaneous tissue in systemic scleroderma. Arch Dermatol. 1972 Jan;105(1):59–66. [PubMed] [Google Scholar]
  12. GREENFIELD A. D., WHITNEY R. J., MOWBRAY J. F. Methods for the investigation of peripheral blood flow. Br Med Bull. 1963 May;19:101–109. doi: 10.1093/oxfordjournals.bmb.a070026. [DOI] [PubMed] [Google Scholar]
  13. Golub M., Zia P., Matsuno M., Horton R. Metabolism of prostaglandins A1 and E1 in man. J Clin Invest. 1975 Dec;56(6):1404–1410. doi: 10.1172/JCI108221. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Jarrett P. E., Morland M., Browse N. L. Treatment of Raynaud's phenomenon by fibrinolytic enhancement. Br Med J. 1978 Aug 19;2(6136):523–525. doi: 10.1136/bmj.2.6136.523. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Kondo H., Rabin B. S., Rodnan G. P. Cutaneous antigen-stimulating lymphokine production by lymphocytes of patients with progressive systemic sclerosis (scleroderma). J Clin Invest. 1976 Dec;58(6):1388–1394. doi: 10.1172/JCI108594. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. LASSEN N. A., LINDBJERG J., MUNCK O. MEASUREMENT OF BLOOD-FLOW THROUGH SKELETAL MUSCLE BY INTRAMUSCULAR INJECTION OF XENON-133. Lancet. 1964 Mar 28;1(7335):686–689. doi: 10.1016/s0140-6736(64)91518-1. [DOI] [PubMed] [Google Scholar]
  17. LeRoy E. C., Downey J. A., Cannon P. J. Skin capillary blood flow in scleroderma. J Clin Invest. 1971 Apr;50(4):930–939. doi: 10.1172/JCI106565. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Nielsen P. E., Nielsen S. L., Holstein P., Poulsen H. L., Hansen E. H., Lassen N. A. Intra-arterial infusion of prostaglandin E1 in normal subjects and patients with peripheral arterial disease. Scand J Clin Lab Invest. 1976 Nov;36(7):633–640. doi: 10.1080/00365517609054488. [DOI] [PubMed] [Google Scholar]
  19. Norton W. L., Nardo J. M. Vascular disease in progressive systemic sclerosis (scleroderma). Ann Intern Med. 1970 Aug;73(2):317–324. doi: 10.7326/0003-4819-73-2-317. [DOI] [PubMed] [Google Scholar]
  20. Sakaguchi S., Kusaba A., Mishima Y., Kamiya K., Nishimura A., Furukawa K., Shionoya S., Kawashima M., Katsumura T., Sakuma A. A multi-clinical double blind study with PGE, (alpha-cyclodextrin clathrate) in patients with ischemic ulcer of the extremities. Vasa. 1978;7(3):263–266. [PubMed] [Google Scholar]
  21. Salem N. B., Morse J. H. Lymphocyte response to mitogens in progressive systemic sclerosis. Arthritis Rheum. 1976 Sep-Oct;19(5):875–882. doi: 10.1002/art.1780190507. [DOI] [PubMed] [Google Scholar]
  22. Stobo J. D., Kennedy M. S., Goldyne M. E. Prostaglandin E modulation of the mitogenic response of human T cells. Differential response of T-cell subpopulations. J Clin Invest. 1979 Nov;64(5):1188–1203. doi: 10.1172/JCI109572. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Szczeklik A., Nizankowski R., Skawinski S., Szczeklik J., Gluszko P., Gryglewski R. J. Successful therapy of advanced arteriosclerosis obliterans with prostacyclin. Lancet. 1979 May 26;1(8126):1111–1114. doi: 10.1016/s0140-6736(79)91792-6. [DOI] [PubMed] [Google Scholar]
  24. Tindall J. P., Whalen R. E., Burton E. E., Jr Medical uses of intra-arterial injections of reserpine. Treatment of Raynaud syndrome and of some vascular insufficiencies of the lower extremities. Arch Dermatol. 1974 Aug;110(2):233–237. [PubMed] [Google Scholar]
  25. Varadi D. P., Lawrence A. M. Suppression of Raynaud's phenomenon by methyldopa. Arch Intern Med. 1969 Jul;124(1):13–18. [PubMed] [Google Scholar]
  26. Whittle B. J., Moncada S., Vane J. R. Comparison of the effects of prostacyclin (PGI2), prostaglandin E1 and D2 on platelet aggregation in different species. Prostaglandins. 1978 Sep;16(3):373–388. doi: 10.1016/0090-6980(78)90216-2. [DOI] [PubMed] [Google Scholar]
  27. Wong W. H., Freedman R. I., Raben S. F., Schwartz S., Levan N. E. Low molecular weight dextran therapy for scleroderma. Effects of dextran 40 on blood flow and capillary filtration coefficient in scleroderma. Arch Dermatol. 1974 Sep;110(3):419–422. doi: 10.1001/archderm.110.3.419. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES